Introduction：Basic information about CAS 31036-80-3|Lofexidine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Lofexidine |
|---|
| CAS Number | 31036-80-3 | Molecular Weight | 259.132 |
|---|
| Density | 1.4±0.1 g/cm3 | Boiling Point | 421.5±35.0 °C at 760 mmHg |
|---|
| Molecular Formula | C11H12Cl2N2O | Melting Point | 215-225 °C |
|---|
| MSDS | / | Flash Point | 208.7±25.9 °C |
|---|
Names
| Name | lofexidine |
|---|
| Synonym | More Synonyms |
|---|
Lofexidine BiologicalActivity
| Description | Lofexidine is a selective α2-receptor agonist, commonly used to alleviate the physical symptoms of heroin and other types of opioid withdrawal[1][2]. |
|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>Adrenergic ReceptorResearch Areas >>Neurological Disease |
|---|
| Target | α2-receptor[1][2]. |
|---|
| References | [1]. Vartak AP, et al. The preclinical discovery of lofexidine for the treatment of opiate addiction. Expert Opin Drug Discov. 2014 Nov;9(11):1371-7. [2]. Gish EC, et al. Lofexidine, an {alpha}2-receptor agonist for opioid detoxification. Ann Pharmacother. 2010 Feb;44(2):343-51. |
|---|
Chemical & Physical Properties
| Density | 1.4±0.1 g/cm3 |
|---|
| Boiling Point | 421.5±35.0 °C at 760 mmHg |
|---|
| Melting Point | 215-225 °C |
|---|
| Molecular Formula | C11H12Cl2N2O |
|---|
| Molecular Weight | 259.132 |
|---|
| Flash Point | 208.7±25.9 °C |
|---|
| Exact Mass | 258.032654 |
|---|
| PSA | 33.62000 |
|---|
| LogP | 3.59 |
|---|
| Vapour Pressure | 0.0±1.0 mmHg at 25°C |
|---|
| Index of Refraction | 1.611 |
|---|
| InChIKey | KSMAGQUYOIHWFS-UHFFFAOYSA-N |
|---|
| SMILES | CC(Oc1c(Cl)cccc1Cl)C1=NCCN1 |
|---|
| Storage condition | -20°C |
|---|
Toxicological Information
CHEMICAL IDENTIFICATION - RTECS NUMBER :
- NJ2568000
- CHEMICAL NAME :
- 2-Imidazoline 2-(1-(2,6-dichlorophenoxy)ethyl)-
- CAS REGISTRY NUMBER :
- 31036-80-3
- LAST UPDATED :
- 198912
- DATA ITEMS CITED :
- 2
- MOLECULAR FORMULA :
- C11-H12-Cl2-N2-O
- MOLECULAR WEIGHT :
- 259.15
HEALTH HAZARD DATAACUTE TOXICITY DATA - TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 8320 ug/kg
- SEX/DURATION :
- female 8-20 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
- REFERENCE :
- NRTXDN Neurotoxicology. (Intox Press, Inc., POB 34075, Little Rock, AR 72203) V.1- 1979- Volume(issue)/page/year: 9,559,1988
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 8320 ug/kg
- SEX/DURATION :
- female 8-20 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - biochemical and metabolic
- REFERENCE :
- NRTXDN Neurotoxicology. (Intox Press, Inc., POB 34075, Little Rock, AR 72203) V.1- 1979- Volume(issue)/page/year: 9,551,1988
|
Safety Information
| Safety Phrases | S24/25 |
|---|
| WGK Germany | 3 |
|---|
Synonyms
| MFCD00865915 |
| 2-{1-[(2,6-dichlorophenyl)oxy]ethyl}-4,5-dihydro-1H-imidazole |
| 2-(a-(2,6-dichlorophenoxy)ethyl)2-imidazoline |
| Lofexidinum [INN-Latin] |
| Lofexidina |
| 1H-Imidazole, 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro- |
| Britlofex |
| Lofexidine |
| (±)-2-[1-(2,6-Dichlorophenoxy)ethyl]-2-imidazoline |
| Lofexidinum |
| Lofexidine [INN:BAN] |
| Lofexidina [INN-Spanish] |
| 2-[1-(2,6-dichlorophenoxy)ethyl]-2-imidazoline |
| UNII:UI82K0T627 |
| (-)-2-[1-(2,6-dichlorophenoxy)-ethyl]-1,3-diazacyclopent-2-ene |
| 2-[1-(2,6-Dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole |
| rac-2-[1-(2,6-dichlorophenoxy)ethyl]-1,3-diazacyclopent-2-ene |
